Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 7/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 5/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160339 | 0.82 | HCRTR2 (0.32) | KMT2A | |
| SCHEMBL5160202 | 0.81 | HTT (0.47) | FKBP1AHTTKMT2A | |
| SCHEMBL5160073 | 0.72 | HTT (0.39) | FKBP1AHTTPREPACE2ALDH1A1 | |
| SCHEMBL19182782 | 0.71 | HTT (0.54) | HTTALDH1A1NPSR1 | |
| SCHEMBL5163745 | 0.71 | HTT (0.48) | FKBP1AHTTPREPALDH1A1CYP3A4 | |
| SCHEMBL15561301 | 0.70 | HTT (0.47) | HTTALDH1A1 | |
| SCHEMBL11584633 | 0.68 | PRCP (0.68) | PREPALDH1A1CYP3A4TSHRNPSR1 | |
| SCHEMBL2768429 | 0.67 | PREP (0.60) | PREPACE2ALDH1A1TSHRNPSR1 | |
| SCHEMBL23034568 | 0.67 | CYP3A4 (0.47) | FKBP1AALDH1A1CYP3A4TSHRKMT2A | |
| SCHEMBL26447162 | 0.66 | ALDH1A1 (0.50) | HTTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | FKBP1A 1684/4885HTT 3765/4885PREP 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.